bulaquine and Malaria

bulaquine has been researched along with Malaria* in 4 studies

Other Studies

4 other study(ies) available for bulaquine and Malaria

ArticleYear
Novel squaramides with in vitro liver stage antiplasmodial activity.
    Bioorganic & medicinal chemistry, 2016, Apr-15, Volume: 24, Issue:8

    A structure-activity relationship study was performed with ten 8-aminoquinoline-squaramides compounds active against liver stage malaria parasites, using human hepatoma cells (Huh7) infected by Plasmodium berghei parasites. In addition, their blood-schizontocidal activity was assessed against chloroquine-resistant W2 strain Plasmodium falciparum. Compound 3 was 7.3-fold more potent than the positive control primaquine against liver-stage parasites, illustrating the importance of the squarate moiety to activity.

    Topics: Antiprotozoal Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Liver; Malaria; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium falciparum; Quinine; Structure-Activity Relationship

2016
Plasmodium cynomolgi: gametocytocidal activity of the anti-malarial compound CDRI 80/53 (elubaquine) in rhesus monkeys.
    Experimental parasitology, 2005, Volume: 111, Issue:1

    The gametocytocidal action of a new enamine analogue of primaquine, elubaquine (compound CDRI 80/53, bulaquine), has been evaluated against Plasmodium cynomolgi B in rhesus monkeys. Colony bred Anopheles stephensi mosquitoes were fed on gametocyte carrying rhesus monkeys prior to and at varying intervals after oral administration of a single dose of elubaquine at doses ranging between 0.63 and 5.00 mg/kg. Complete loss of oocyst development and mosquito infectivity was observed within 24 h after administering a single 1.25 mg/kg dose, while higher dose of 3.75 mg/kg inhibited oocyst development within 5 h, indicating gametocytocidal action of the compound. Elubaquine did not show any action against developing oocysts in the vector.

    Topics: Animals; Anopheles; Antimalarials; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Insect Vectors; Macaca mulatta; Malaria; Male; Plasmodium cynomolgi; Primaquine

2005
Causal prophylactic activity of a new 8-aminoquinoline derivative against Plasmodium cynomolgi B in rhesus monkeys.
    The Indian journal of medical research, 1990, Volume: 91

    A new 8-aminoquinoline derivative, N1-(3-acetyl-4-5-dihydro-2 furanyl)-N4-(6-methoxy-8-quinolinyl)1,4-pentanediamine, synthesized at CDRI, Lucknow, showed causal prophylactic activity at 3.16 mg/kg x 3 doses (on day -1, 0 and +1) against sporozoite induced P. cynomolgi B infection in rhesus monkeys. Single dose of 10 mg/kg of this compound on day 0 also prevented establishment of patient infection. Activity of the compound was comparable to that of primaquine (with causal prophylactic activity at 1.78 mg/kg in three day test and at 10.0 mg/kg in single dose test).

    Topics: Animals; Antimalarials; Macaca mulatta; Malaria; Primaquine

1990
Radical curative activity of a new 8-aminoquinoline derivative (CDRI 80/53) against Plasmodium cynomolgi B in monkeys.
    The American journal of tropical medicine and hygiene, 1989, Volume: 41, Issue:6

    An analogue of primaquine, N1-(3-acetyl-4-5-dihydro-2-furanyl)-N4-(6-methoxy-8-quinolinyl) 1,4-pentanediamine, CDRI Code 80/53), has been evaluated for anti-relapse activity against sporozoite induced Plasmodium cynomolgi B infection in rhesus monkeys. The compound has shown 100% curative anti-relapse activity at 1.25 mg/kg x 7 day dose schedule, thereby giving a primaquine index of 0.8. The compound is currently under Phase-I clinical trials.

    Topics: Aminoquinolines; Animals; Antimalarials; Drug Evaluation, Preclinical; Macaca mulatta; Malaria; Molecular Structure; Primaquine

1989